23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Cogent Biosciences, Inc. › 2025-2026

Cogent Biosciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Cogent Biosciences, Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 328Asset managers, any item
  • 2,172Fund votes
  • June 9, 2026Meeting date

Results at a glance

Meeting of June 9, 2026: 5 items on Cogent Biosciences, Inc.’s Form 8-K, filed June 11, 2026: 3 elected · 2 passed (calculated).

Dissent

Notable dissent: 3 directors (16.1%, 13.3%, 13.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cogent Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cogent Biosciences, Inc.

These tallies are Cogent Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cogent Biosciences, Inc. — official shareholder meeting results, meeting held June 9, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Chris Cain, Ph.D. 124,356,809---- 18,837,09211,240,612 87%Elected—
Elect Director: Arlene Morris 120,180,517---- 23,013,38411,240,612 84%Elected—
Elect Director: Todd Shegog 124,143,441---- 19,050,46011,240,612 87%Elected—
2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm 154,001,553399,36733,593 --0 99.7%Passed (calculated)—
3. Advisory Vote on Executive Compensation 129,183,84613,977,44932,606 --11,240,612 90%Passed (calculated)—

Source: Cogent Biosciences, Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.

How asset managers voted at the Cogent Biosciences, Inc. 2025-2026 meeting

328 asset managers disclosed a vote on at least one Cogent Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Chris Cain, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 124,356,809WITHHELD: 18,837,092
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dr. Chris Cain

Cogent Biosciences, Inc.’s own tally for this item (“Elect Director: Chris Cain, Ph.D.”): 124,356,809 for, 18,837,092 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on were approved.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 64,061,840 for, 4,628,759 withheld, 227,991 abstained.

FOR
FOR: 64,061,840ABSTAIN: 227,991WITHHOLD: 4,628,759
Largest asset managers voting on “Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and un” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity25,292,6870 028,800For
Vanguard14,120,0350 4030,000For
BlackRock8,086,1960 00For
State Street2,647,7600 03,039For
Lord Abbett2,380,2330 00For
T. Rowe Price2,297,0630 00For
Invesco1,434,2040 00For
JANUS INVESTMENT FUND1,408,2540 00For
Charles Schwab1,244,0960 00For
TIAA696,5350 00For
American Century00 0681,618Withhold
RBB FUND, INC.32,4950 0608,486Mixed
MFS00 0528,727Withhold
ALGER FUNDS00 0483,031Withhold
Equitable347,2260 0108,420Mixed
Jackson National445,2270 00For
Principal00 0429,689Withhold
Brighthouse333,5460 045,945Mixed
ALGER FUNDS II00 0339,731Withhold
Voya339,0640 00For
Hartford324,6100 00For
Federated Hermes264,4640 00For
Delaware/Macquarie00 0230,000Withhold
QUANTITATIVE MASTER SERIES LLC228,8170 00For
AIG/SunAmerica00 0228,014Withhold

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Elect Director: Arlene Morris

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 120,180,517WITHHELD: 23,013,384
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Arlene M. Morris

Cogent Biosciences, Inc.’s own tally for this item (“Elect Director: Arlene Morris”): 120,180,517 for, 23,013,384 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on were approved.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 62,215,493 for, 6,474,561 withheld, 228,536 abstained.

FOR
FOR: 62,215,493ABSTAIN: 228,536WITHHOLD: 6,474,561
Largest asset managers voting on “Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and un” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity25,292,6870 028,800For
Vanguard14,112,2920 4937,734For
BlackRock8,086,1960 00For
State Street2,647,7600 03,039For
Lord Abbett2,380,2330 00For
T. Rowe Price2,297,0630 00For
Invesco1,434,2040 00For
JANUS INVESTMENT FUND1,408,2540 00For
Charles Schwab00 01,244,096Withhold
TIAA696,5350 00For
American Century00 0681,618Withhold
RBB FUND, INC.32,4950 0608,486Mixed
MFS00 0528,727Withhold
ALGER FUNDS00 0483,031Withhold
Equitable347,2260 0108,420Mixed
Jackson National445,2270 00For
Principal00 0429,689Withhold
Brighthouse333,5460 045,945Mixed
ALGER FUNDS II00 0339,731Withhold
Voya339,0640 00For
Hartford324,6100 00For
Federated Hermes00 0264,464Withhold
Delaware/Macquarie00 0230,000Withhold
QUANTITATIVE MASTER SERIES LLC228,8170 00For
AIG/SunAmerica00 0228,014Withhold

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Elect Director: Todd Shegog

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 124,143,441WITHHELD: 19,050,460
Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Todd Shegog

Cogent Biosciences, Inc.’s own tally for this item (“Elect Director: Todd Shegog”): 124,143,441 for, 19,050,460 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected and each of the other proposals voted on were approved.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 64,054,105 for, 4,636,493 withheld, 227,992 abstained.

FOR
FOR: 64,054,105ABSTAIN: 227,992WITHHOLD: 4,636,493
Largest asset managers voting on “Election of the three Class II director nominees to serve until the 2029 Annual Meeting of Stockholders and un” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity25,292,6870 028,800For
Vanguard14,112,3000 4137,734For
BlackRock8,086,1960 00For
State Street2,647,7600 03,039For
Lord Abbett2,380,2330 00For
T. Rowe Price2,297,0630 00For
Invesco1,434,2040 00For
JANUS INVESTMENT FUND1,408,2540 00For
Charles Schwab1,244,0960 00For
TIAA696,5350 00For
American Century00 0681,618Withhold
RBB FUND, INC.32,4950 0608,486Mixed
MFS00 0528,727Withhold
ALGER FUNDS00 0483,031Withhold
Equitable347,2260 0108,420Mixed
Jackson National445,2270 00For
Principal00 0429,689Withhold
Brighthouse333,5460 045,945Mixed
ALGER FUNDS II00 0339,731Withhold
Voya339,0640 00For
Hartford324,6100 00For
Federated Hermes264,4640 00For
Delaware/Macquarie00 0230,000Withhold
QUANTITATIVE MASTER SERIES LLC228,8170 00For
AIG/SunAmerica00 0228,014Withhold

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 129,183,846AGAINST: 13,977,449

Prior year: 99.1% for (June 4, 2025 meeting) ▼ 8.9 pts

Details: description as filed, official tally, votes by 328 asset managers

Description as filed by funds: Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.

Cogent Biosciences, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 129,183,846 for, 13,977,449 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 91 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity25,321,4870 00For
Vanguard14,142,3287,747 00For
BlackRock8,086,1960 00For
State Street7,4292,643,370 00Against
Lord Abbett2,380,2330 00For
T. Rowe Price2,297,0630 00For
Invesco01,434,204 00Against
JANUS INVESTMENT FUND1,408,2540 00For
Charles Schwab1,244,0960 00For
TIAA696,5350 00For
American Century0681,618 00Against
RBB FUND, INC.640,9810 00For
MFS528,7270 00For
ALGER FUNDS0483,031 00Against
Equitable455,6460 00For
Jackson National0445,227 00Against
Principal429,6890 00For
Brighthouse154,888224,603 00Mixed
ALGER FUNDS II0339,731 00Against
Voya339,0640 00For
Hartford324,6100 00For
Federated Hermes264,4640 00For
Delaware/Macquarie230,0000 00For
QUANTITATIVE MASTER SERIES LLC228,8170 00For
AIG/SunAmerica228,0140 00For

Fund voting reports, all 91 managers: 62,203,014 for, 6,707,491 against, 8,093 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 258 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity23,019,7710 00For
Janus Henderson8,911,3180 00For
BlackRock6,439,04531,530 00For
Fairmount Funds Management LLC5,503,4180 00For
State Street53,1765,441,272 00Against
RTW INVESTMENTS, LP4,560,9010 00For
DEERFIELD MANAGEMENT COMPANY, L.P.4,094,6590 00For
Kynam Capital Management, LP00 03,726,686Withhold
GEODE CAPITAL MANAGEMENT, LLC3,700,0740 00For
T. Rowe Price3,531,9280 00For
Commodore Capital LP2,888,0070 00For
LORD, ABBETT & CO. LLC2,850,6430 00For
Octagon Capital Advisors LP2,605,0000 00For
Invesco02,544,179 00Against
Wellington2,426,9850 00For
Venrock Adviser, LLC2,000,0000 00For
PICTET ASSET MANAGEMENT SA1,833,2030 00For
Woodline Partners LP1,723,8750 00For
Siren, L.L.C.1,709,2790 00For
Vestal Point Capital, LP1,523,3810 00For
Candriam S.C.A.01,514,977 00Against
Charles Schwab1,247,1050 00For
Vanguard1,241,7240 00For
FRED ALGER MANAGEMENT, LLC43,9581,160,698 00Against
Deep Track Capital, LP1,200,0000 00For

Institutional-manager reports, all 258 managers: 103,980,282 for, 13,027,295 against, 3,726,686 withheld, 51,106 abstained, 308 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 154,001,553AGAINST: 399,367

Prior year: 99.9% for (June 4, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 92 asset managers

Description as filed by funds: Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.

Cogent Biosciences, Inc.’s own tally for this item (“2. Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm”): 154,001,553 for, 399,367 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 92 asset managers below reported 68,910,553 for, 105 against, 8,093 abstained.

FOR
FOR: 68,910,553AGAINST: 105ABSTAIN: 8,093
Largest asset managers voting on “Ratification of the selection of PricewaterhouseCoopers LLP as the Company's independent registered public acc” at Cogent Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity25,321,4870 00For
Vanguard14,150,0741 00For
BlackRock8,086,1960 00For
State Street2,650,695104 00For
Lord Abbett2,380,2330 00For
T. Rowe Price2,297,0630 00For
Invesco1,434,2040 00For
JANUS INVESTMENT FUND1,408,2540 00For
Charles Schwab1,244,0960 00For
TIAA696,5350 00For
American Century681,6180 00For
RBB FUND, INC.640,9810 00For
MFS528,7270 00For
ALGER FUNDS483,0310 00For
Equitable455,6460 00For
Jackson National445,2270 00For
Principal429,6890 00For
Brighthouse379,4910 00For
ALGER FUNDS II339,7310 00For
Voya339,0640 00For
Hartford324,6100 00For
Federated Hermes264,4640 00For
Delaware/Macquarie230,0000 00For
QUANTITATIVE MASTER SERIES LLC228,8170 00For
AIG/SunAmerica228,0140 00For

Showing the 25 largest of 92 asset managers. All 92 are in the interactive database (link above).

Largest Cogent Biosciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 170,773,803 shares outstanding at the time of that meeting.

Fund voting reports: top Cogent Biosciences, Inc. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.83%
2Vanguard 8.29%
3BlackRock 4.74%
4State Street 1.55%
5Lord Abbett 1.39%
6T. Rowe Price 1.35%
7Invesco 0.84%
8JANUS INVESTMENT FUND 0.82%
9Charles Schwab 0.73%
10TIAA 0.41%
Institutional-manager reports: top Cogent Biosciences, Inc. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 13.48%
2Janus Henderson 5.22%
3BlackRock 3.79%
4Fairmount Funds Management LLC 3.22%
5State Street 3.22%
6RTW INVESTMENTS, LP 2.67%
7DEERFIELD MANAGEMENT COMPANY, L.P. 2.40%
8Kynam Capital Management, LP 2.18%
9GEODE CAPITAL MANAGEMENT, LLC 2.17%
10T. Rowe Price 2.07%

Reported Cogent Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Cogent Biosciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)23,122,748 13.54%Form 13F, quarter ended March 31, 2026
Entities affiliated with FMR LLC16,569,256 9.70%Proxy statement (DEF 14A), table as of April 13, 2026
BlackRock16,045,014 9.40%Form 13F, quarter ended March 31, 2026
Entities affiliated with Fairmount Funds Management LLC15,356,918 8.99%Proxy statement (DEF 14A), table as of April 13, 2026
Fairmount Funds Management LLC15,356,918 8.99%Schedule 13D, filed March 31, 2026
Vanguard Group11,514,326 6.74%Form 13F, quarter ended March 31, 2026
Entities affiliated with BlackRock, Inc.11,370,224 6.66%Proxy statement (DEF 14A), table as of April 13, 2026
Entities affiliated with Deerfield Mgmt, L.P.9,053,118 5.30%Proxy statement (DEF 14A), table as of April 13, 2026
State Street5,663,543 3.32%Form 13F, quarter ended March 31, 2026
Andrew Robbins5,193,752 3.04%Proxy statement (DEF 14A), table as of April 13, 2026

Percentages above are of 170,773,803 shares outstanding, as reported by Cogent Biosciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Cogent Biosciences, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 328 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,172 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding, advisory basis, of the compensation of the Company's named… — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Cogent Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cogent Biosciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Cogent Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Cogent Biosciences (COGT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/cogent-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.